Alvina sells ANIP 28.07: ANI Pharmaceuticals Downgraded by Zacks to âUnderperformâ (ANIP)
ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by Zacks from a âneutralâ rating to an âunderperformâ rating in a research report issued on Tuesday. They currently have a $27.90 price objective on the stock. Zacksâs price target suggests a ... ...
24 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home